Novo Nordisk beats on Wegovy sales, expects slower 2025 growth
Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss drugs towards the end of the year. Novo saw But Novo said Wednesday it expects slower growth in 2025 compared to the prior year.
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug Wegovy doubled in the fourth quarter, but the Danish ...
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face ...
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...
In a 72-week study, Zepbound's mean weight loss was 20.2%, while Wegovy's was 13.7% ... did not perform as well as expected in a phase 3 study. CagriSema could still be a commercial success ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback